8-K: Cyclo Therapeutics Secures $1 Million in Convertible Note Financing from Rafael Holdings

Cyclo Therapeutics has entered into a sixth amended agreement with Rafael Holdings, issuing a $1 million convertible promissory note to support working capital and general corporate purposes.

Summary

• Cyclo Therapeutics has secured a $1 million convertible promissory note from Rafael Holdings.
• This agreement is the sixth amendment to a series of note purchase agreements between the two companies.
• The note matures on December 21, 2024, and carries a 5% annual interest rate.
• The principal amount of the note is convertible into shares of Cyclo Therapeutics' common stock under certain conditions.
• These conditions include a qualified financing event, a sale transaction, or at the option of Rafael Holdings.
• The proceeds from the note will be used for working capital and general corporate purposes.
• Rafael Holdings currently holds approximately 31.4% of Cyclo Therapeutics' common stock.
• There is an existing merger agreement between Cyclo Therapeutics and a subsidiary of Rafael Holdings, which is subject to shareholder approval and other conditions.

Sentiment

Score: 4

Explanation: The document indicates a company that is reliant on debt financing and has a history of amending financing agreements, which suggests financial challenges. The pending merger adds uncertainty. The sentiment is therefore negative.

Positives

• Cyclo Therapeutics has secured additional funding to support its operations.
• The convertible note structure provides flexibility for both the company and the investor.
• The funds will be used for working capital and general corporate purposes, which can support growth and stability.
• The existing relationship with Rafael Holdings provides a reliable source of capital.

Negatives

• The company is relying on debt financing, which could increase financial risk.
• The note is convertible, which could lead to dilution of existing shareholders if converted to equity.
• The company has a history of amending and restating note purchase agreements, which may indicate financial instability.
• The interest rate on the note increases to 12% upon an event of default, which could be a significant burden.

Risks

• The company's reliance on debt financing could increase its financial risk.
• The convertible nature of the note could lead to dilution of existing shareholders.
• Failure to meet the terms of the note could trigger an event of default and increase the interest rate to 12%.
• The merger with Rafael Holdings is subject to conditions and shareholder approval, which introduces uncertainty.
• The company's history of amending and restating note purchase agreements may indicate financial instability.

Future Outlook

The company intends to use the proceeds of the note for working capital and general corporate purposes, and the merger with Rafael Holdings is pending.

Management Comments

• The company intends to use the proceeds of the Note for working capital and general corporate purposes.

Industry Context

This financing activity is not uncommon for small biotech companies seeking to fund operations and development. The repeated amendments to the note purchase agreement and the pending merger suggest a company in need of capital and potentially undergoing significant strategic changes.

Comparison to Industry Standards

• The use of convertible notes is a common financing method for early-stage biotech companies, similar to companies like Athersys and Ocugen, which have also used convertible debt to fund operations.
• The interest rate of 5% is relatively standard for this type of financing, although the increase to 12% upon default is a significant risk.
• The repeated amendments to the note purchase agreement are not typical and may indicate financial challenges, unlike more stable companies that secure funding through more straightforward means.
• The pending merger with Rafael Holdings is a significant event, similar to other biotech companies that have merged to consolidate resources and expertise, such as the merger between Celgene and Bristol-Myers Squibb.

Related Party Transactions

• The convertible note was issued to Rafael Holdings, which is a related party holding approximately 31.4% of the company's common stock.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted to equity.
• Employees may be impacted by the company's financial situation and the pending merger.
• Creditors may be concerned about the company's increasing debt.
• Customers and suppliers may be impacted by any changes in the company's operations.

Next Steps

• The company will use the proceeds for working capital and general corporate purposes.
• The company will need to manage the debt and interest payments.
• The company will need to seek shareholder approval for the merger with Rafael Holdings.
• The company will need to monitor the conditions for conversion of the note.

Key Dates

Keywords

convertible note, financing, Rafael Holdings, debt, working capital, merger, common stock, dilution, promissory note, capital raise